CXCR4 Based Therapeutics for Non-Small Cell Lung Cancer (NSCLC)
Lung cancer is the second most common malignancy. Unfortunately, despite advances in multimodality therapeutics for the disease, the overall five-year survival rate among newly diagnosed lung cancer patients remains in the range region of 15%. In addition, although immune checkpoint inhibitors are i...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-09-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2077-0383/7/10/303 |